Iovance Biotherapeutics Stock Forum

$Iovance Biotherapeutics(IOVA.US)$ Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
4 MINUTES AGO, 6:30 AM EST
VIA GLOBENEWSWIRE

hhh, reenter.. I should have stopped daytrade better swing for biotech, easier to get gain if got FDA approval...
$Biotechnology(BK2069.US)$
$Iovance Biotherapeutics(IOVA.US)$

$Iovance Biotherapeutics(IOVA.US)$
Shorties gonna b the Johnny come lately?
$AMC Entertainment(AMC.US)$$GameStop(GME.US)$$Uber Technologies(UBER.US)$$DraftKings(DKNG.US)$$ARK Innovation ETF(ARKK.US)$$Tesla(TSLA.US)$$Affirm Holdings(AFRM.US)$$PDD Holdings(PDD.US)$

4 FDA approvals last week
1 PDUFA event left in Feb 2024
Last week’s PDUFAs:
$AstraZeneca(AZN.US)$ : Approved 2/16
⇒ Tagrisso (osimertinib) + chemotherapy
⇒ NSCLC
⇒ sNDA
⇒ PDUFA: Q1 2024
$Iovance Biotherapeutics(IOVA.US)$ : Approved 2/16
⇒  AMTAGVI™ (lifileucel)
⇒ Melanoma
⇒ BLA
⇒ PDUFA: 02/24/24
$ROCHE HOLDING AG(RHHBY.US)$ : Approved 2/16
⇒ Xolair® (omalizumab)
⇒ IgE-mediated food allergy
⇒ sBLA
⇒ PDUFA: Q1 2024
$IPSEY & $Merrimack Pharmaceuticals(MACK.US)$ : Approved 2/13
⇒ ...

$Iovance Biotherapeutics(IOVA.US)$
02/20/2024 - 06:30 AM
SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per sh...

$Iovance Biotherapeutics(IOVA.US)$ Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2 MINUTES AGO, 6:30 AM EST
VIA GLOBENEWSWIRE